The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

Table 4 Patient characteristics and parameters.

Parameter	Total	Group A (N = 10)	Group B (N = 18)	Group C (N = 19)
Gender
Male	84%	100%	100%	68,7%
Female	16%	0%	0%	31,3%
HIV-1 subtype
Patients with subtype B	69%	80%	64%	67%
Patients with non-B subtype	31%	20%	36%	33%
Treatment history
Mean duration under ART in months (mean)	66	80	88	54
Current active drug score (mean)	-	1.5	1.3	0.5
HIV-1 RNA [copies/ml; median]
Baseline	20,163	26,950	8,800	42,600
CD4 cell counts [cells/μl; median]
Baseline	260	291	307	246

Patient characteristics and parameters. All patients were categorized in three groups as described throughout the article: Group A (ATV and or SQV), group B (ATV and or SQV plus L76V selecting drug LPV, APV or DRV) and group C (L76V selecting drug plus optimized backbone therapy).

ISSN: 1742-6405